Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines

Abstract Aim We aim to determine the cost‐effectiveness of dapagliflozin in addition to standard therapy versus standard therapy alone among patients with heart failure with reduced ejection fraction (HFrEF) using the public healthcare provider's perspective in the Philippines. Methods and resu...

Full description

Bibliographic Details
Main Authors: Victor L. Mendoza, Bernadette A. Tumanan‐Mendoza, Felix Eduardo R. Punzalan
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:ESC Heart Failure
Subjects:
dapagliflozin
heart failure
incremental cost‐effectiveness ratio
Online Access:https://doi.org/10.1002/ehf2.13583

Internet

https://doi.org/10.1002/ehf2.13583

Similar Items